Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles

Gilead Sciences has partnered with or acquired five cancer companies in the past four months, with each deal anchored by a different approach to immuno-oncology.

The biotech’s largest deal -- a $4.9 billion acquisition of Forty Seven Inc. that closed in April -- gave it mAbs that act as checkpoint inhibitors for macrophages, promoting phagocytosis of tumor cells. ...